Logo image of AVCN.CA

AVICANNA INC (AVCN.CA) Stock Fundamental Analysis

TSX:AVCN - Toronto Stock Exchange - CA05368K1003 - Common Stock - Currency: CAD

0.37  +0.03 (+7.25%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AVCN. AVCN was compared to 35 industry peers in the Pharmaceuticals industry. While AVCN seems to be doing ok healthwise, there are quite some concerns on its profitability. AVCN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AVCN has reported negative net income.
In the past year AVCN has reported a negative cash flow from operations.
AVCN had negative earnings in each of the past 5 years.
In the past 5 years AVCN always reported negative operating cash flow.
AVCN.CA Yearly Net Income VS EBIT VS OCF VS FCFAVCN.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of AVCN (-33.22%) is worse than 67.57% of its industry peers.
AVCN has a worse Return On Equity (-396.25%) than 81.08% of its industry peers.
Industry RankSector Rank
ROA -33.22%
ROE -396.25%
ROIC N/A
ROA(3y)-66.22%
ROA(5y)-70.85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVCN.CA Yearly ROA, ROE, ROICAVCN.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 2K 4K 6K

1.3 Margins

AVCN has a Gross Margin of 50.99%. This is in the better half of the industry: AVCN outperforms 72.97% of its industry peers.
AVCN's Gross Margin has declined in the last couple of years.
AVCN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.4%
GM growth 5YN/A
AVCN.CA Yearly Profit, Operating, Gross MarginsAVCN.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

AVCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AVCN has more shares outstanding
The number of shares outstanding for AVCN has been increased compared to 5 years ago.
Compared to 1 year ago, AVCN has an improved debt to assets ratio.
AVCN.CA Yearly Shares OutstandingAVCN.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
AVCN.CA Yearly Total Debt VS Total AssetsAVCN.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -4.47, we must say that AVCN is in the distress zone and has some risk of bankruptcy.
AVCN's Altman-Z score of -4.47 is on the low side compared to the rest of the industry. AVCN is outperformed by 64.86% of its industry peers.
AVCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.47
ROIC/WACCN/A
WACC8.59%
AVCN.CA Yearly LT Debt VS Equity VS FCFAVCN.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.83 indicates that AVCN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.83, AVCN is doing worse than 81.08% of the companies in the same industry.
A Quick Ratio of 0.43 indicates that AVCN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.43, AVCN is doing worse than 75.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.43
AVCN.CA Yearly Current Assets VS Current LiabilitesAVCN.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

4

3. Growth

3.1 Past

AVCN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.00%, which is quite impressive.
Looking at the last year, AVCN shows a very strong growth in Revenue. The Revenue has grown by 109.74%.
Measured over the past years, AVCN shows a very strong growth in Revenue. The Revenue has been growing by 168.65% on average per year.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61%
Revenue 1Y (TTM)109.74%
Revenue growth 3Y120.33%
Revenue growth 5Y168.65%
Sales Q2Q%0.38%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVCN.CA Yearly Revenue VS EstimatesAVCN.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
AVCN.CA Yearly EPS VS EstimatesAVCN.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVCN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVCN.CA Price Earnings VS Forward Price EarningsAVCN.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVCN.CA Per share dataAVCN.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1 0.15 0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVCN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVICANNA INC

TSX:AVCN (3/7/2025, 7:00:00 PM)

0.37

+0.03 (+7.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14
Earnings (Next)03-28 2025-03-28/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners14.33%
Ins Owner ChangeN/A
Market Cap40.78M
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.64
P/FCF N/A
P/OCF N/A
P/B 23.76
P/tB 52.28
EV/EBITDA N/A
EPS(TTM)-0.07
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.23
BVpS0.02
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.22%
ROE -396.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.99%
FCFM N/A
ROA(3y)-66.22%
ROA(5y)-70.85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.4%
GM growth 5YN/A
F-Score6
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.95%
Cap/Sales 0.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.43
Altman-Z -4.47
F-Score6
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)56.12%
Cap/Depr(5y)223.29%
Cap/Sales(3y)9.74%
Cap/Sales(5y)905.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)109.74%
Revenue growth 3Y120.33%
Revenue growth 5Y168.65%
Sales Q2Q%0.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.62%
OCF growth 3YN/A
OCF growth 5YN/A